News >

SOLO-1 Data Encourage Molecular Testing Immediately at Ovarian Cancer Diagnosis

Ellie Leick
Published: Wednesday, Jul 17, 2019

Thomas Herzog, MD

Thomas Herzog, MD

A key message from the phase III SOLO-1 trial is that patients with ovarian cancer should be tested for BRCA mutations quickly after diagnosis to inform physicians what treatment will be most effective, explained Thomas Herzog, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication